17:44 , May 11, 2018 |  BC Week In Review  |  Clinical News

Sol-Gel reports Phase II data for Epsolay in rosacea

In February, Sol-Gel Technologies Ltd. (NASDAQ:SLGL) said once-daily Epsolay (formerly VERED) met the co-primary endpoints in a Phase II trial in 92 patients with rosacea. Data from the double-blind, U.S. trial were presented at the...
08:00 , Dec 17, 2012 |  BC Week In Review  |  Clinical News

E-BPO: Phase II data

A double-blind, U.S. Phase II trial in 92 patients with rosacea showed that 53% of patients receiving 5% E-BPO achieved the co-primary endpoint of a 2-grade improvement in IGA from baseline to week 12 vs....